Fig. 2From: CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathwaysS109 induces cell-cycle arrest and regulates the expression of cell cycle-related proteins in glioma cells. a, c U87 and U251 cells were treated with S109 for 12 h. The cells were stained with PI and evaluated using a flow cytometer. b, d Quantitative analysis of the cell-cycle-phase distribution of the cells in the control group and the S109-treated group. e, f U87 cells were treated with 0.1 % DMSO or S109 for 12 h or treated with 2 μM S109 for different durations (0–12 h). The cells were then harvested and examined through western blot analysis with the indicated antibodiesBack to article page